Moleculin Biotech, Inc.
MBRXMoleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing oncology drugs and treatments for difficult-to-treat cancers. The company specializes in the research and development of small molecule therapeutics targeting cancer metabolism, tumor microenvironment, and resistant cancer cells. Moleculin's pipeline includes compounds designed for oral administration, aiming to address unmet medical needs in oncology.
Company News
Over 100 pharmaceutical companies are actively developing 150+ pipeline drugs for Acute Myeloid Leukemia (AML), with approximately 10 drugs in late-stage development and 50+ in mid and early stages, focusing on targeted therapies and personalized treatment approaches.
Moleculin Biotech, a late-stage pharmaceutical company, presented its top five reasons for why investors should pay attention to the company in 2025, including updates on its lead drug candidate Annamycin and other pipeline programs.
Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
